Korro Bio (KRRO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
The annual meeting will be held virtually on June 10, 2026, with voting open to shareholders of record as of April 13, 2026.
Shareholders will vote on electing two Class I directors, a non-binding say-on-pay proposal, and ratification of the external auditor.
Proxy materials are distributed via internet access, with paper copies available upon request.
The board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Election of Nessan Bermingham and Rachel Meyers as Class I directors for terms expiring in 2029.
Advisory vote on executive compensation (say-on-pay).
Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026.
Procedures for shareholder proposals and nominations for the 2027 annual meeting are outlined, with deadlines and requirements specified.
Board of directors and corporate governance
The board is divided into three classes with staggered three-year terms; current board consists of seven members.
Majority of directors are independent under Nasdaq rules; only the CEO is not independent.
Board committees include audit, compensation, and nominating/governance, each with defined charters and independence requirements.
Directors are expected to attend board and committee meetings and the annual meeting.
Code of Business Conduct and Ethics and a compensation recovery policy are in place.
Latest events from Korro Bio
- Director elections, executive pay, and auditor ratification headline the annual meeting agenda.KRRO
Proxy filing16 Apr 2026 - KRRO-121 advances as a first-in-class RNA editing therapy for hyperammonemia, with key milestones ahead.KRRO
Corporate presentation23 Mar 2026 - RNA editing biotech registers 7.65M shares for resale after $85M private placement.KRRO
Registration Filing13 Mar 2026 - KRRO-121 advanced, AATD program pivoted, and $85M financing extended cash runway into 2028.KRRO
Q4 202512 Mar 2026 - First-in-class RNA editing therapy for ammonia disorders targets late 2026 clinical trials.KRRO
Analyst Day 20262 Feb 2026 - Lead RNA editing therapy for alpha-1 antitrypsin deficiency nears clinical stage with strong preclinical data.KRRO
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - RNA editing platform advances lead therapy for alpha-1 antitrypsin deficiency toward clinical trials.KRRO
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - RNA editing platform advances toward clinical trials and expands via Novo Nordisk partnership.KRRO
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - RNA editing platform advances with lead program and Novo Nordisk partnership, runway into 2026.KRRO
Chardan's 8th Annual Genetic Medicines Conference20 Jan 2026